Health Technology · Pharmaceuticals: Major · NSE: ALKEM · data 2026-10-09
Alkem Laboratories Ltd.
Health check: Strong (6.9/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹5,279
Market cap
₹62,663 cr
P/E
29.3
P/B
—
ROE
17.8%
ROCE
17.8%
Debt / equity
0.15
Dividend yield
1.01%
1-year return
-4.4%
52-week high
₹5,933.5
52-week low
₹5,051
Operating margin
17.5%
Growth
| Revenue (last 12 months) | ₹15,081 cr |
| Net profit (last 12 months) | ₹2,158 cr |
| Sales growth, 3 years (yearly) | 8.2% |
| Profit growth, 3 years (yearly) | 32.7% |
Chart patterns
- Descending triangle — forming (key level ₹5,051)
Similar companies
Glenmark Pharmaceuticals Limited (GLENMARK) · Biocon Limited (BIOCON) · Abbott India Limited (ABBOTINDIA) · Gland Pharma Ltd. (GLAND) · IPCA Laboratories Limited (IPCALAB)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ALKEM in NSE Scanner →